P2 receptors and cancer

Trends in Pharmacological Sciences

Volumn 27, Issue 4, 2006, Pages 211-217

  White, Nicholas ^a   Burnstock, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 METHYLTHIOADENOSINE TRIPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 2' O (4 DIBENZOYL)ADENOSINE TRIPHOSPHATE; 3' O (4 DIBENZOYL)ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE; PURINE P2 RECEPTOR; PURINE P2X5 RECEPTOR; PURINE P2X7 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y11 RECEPTOR; PURINE P2Y2 RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

APOPTOSIS; CANCER CELL; CANCER TISSUE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEST TIGHTNESS; CLINICAL TRIAL; COLON TUMOR; DYSPNEA; FLUSHING; HEADACHE; HUMAN; HYDROLYSIS; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION;

EID: 33645977207     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.02.004     Document Type: Review

References (53)

1. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 36 (1997) 1127-1139
2. Burnstock G., and Knight G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240 (2004) 31-304
3. Burnstock G. Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin. Med. 2 (2002) 45-53
4. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
5. King B.F., et al. The P2Y receptors. In: Girdlestone D. (Ed). The IUPHAR Compendium of Receptor Characterisation and Classification (2000), IUPHAR Media 306-320
6. Zimmermann H. Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev. Res. 52 (2001) 44-56
7. Vorhoff T., et al. Cloning and characterisation of the ecto-nucleotidase NTPDase3 from rat brain: predicted secondary structure and relation to other members of the E-NTPDase family and actin. Purinergic Signalling 1 (2005) 259-270
8. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J. Cell. Physiol. 114 (1983) 279-283
9. Rapaport E. Experimental cancer therapy in mice by adenine nucleotides. Eur. J. Cancer Clin. Oncol. 24 (1988) 1491-1497
10. Rapaport E., and Fontaine J. Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem. Pharmacol. 38 (1989) 4261-4266
11. Rapaport E. Mechanisms of anticancer activities of adenine nucleotides in tumor-bearing hosts. Ann. N. Y. Acad. Sci. 603 (1990) 142-149
12. Estrela J.M., et al. Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat. Med. 1 (1995) 84-88
13. Obrador E., et al. Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo. Biochem. J. 325 (1997) 183-189
14. Merighi S., et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol. Ther. 100 (2003) 31-48
15. Rapaport E., and Fontaine J. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 1662-1666
16. Abraham E.H., et al. ATP in the treatment of advanced cancer. Curr. Top. Mem. 54 (2003) 415-452
17. 7 receptors. Cell Tissue Res. 321 (2005) 411-418
18. White N., et al. P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett. 224 (2005) 81-91
19. Greig A.V., et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J. Invest. Dermatol. 121 (2003) 315-327
20. Coutinho-Silva R., et al. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G1024-G1035
21. Hopfner M., et al. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem. Biophys. Res. Commun. 251 (1998) 811-817
22. 2-receptors. Br. J. Cancer 86 (2002) 636-644
23. Schafer R., et al. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 285 (2003) L376-L385
24. 12. FEBS Lett. 513 (2002) 179-183
25. Morrone F.B., et al. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J. Neurooncol. 64 (2003) 211-218
26. 1 receptor stimulate mitogen-activated protein kinases and induce apoptosis. J. Biol. Chem. 276 (2001) 16379-16390
27. 7 receptor-mediated apoptosis of human cervical epithelial cells. Am. J. Physiol. Cell Physiol. 287 (2004) C1349-C1358
28. Vandewalle B., et al. Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium. Cancer Lett. 85 (1994) 47-54
29. Dixon C.J., et al. Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. Br. J. Cancer 75 (1997) 34-39
30. Slater M., et al. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res. Treat. 83 (2004) 1-10
31. Popper L.D., and Batra S. Calcium mobilisation and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell Calcium 14 (1993) 209-218
32. 2 receptors in human ovarian cancer cells. Mol. Hum. Reprod. 6 (2000) 435-442
33. Di Virgilio F., et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97 (2001) 587-600
34. Di Virgilio F., et al. P2 receptors meet the immune system. Trends Pharmacol. Sci. 22 (2001) 5-7
35. 7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99 (2002) 706-708
36. Conigrave A.D., et al. Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. Biochem. Pharmacol. 60 (2000) 1585-1591
37. 7 in human hematopoietic cell lines and leukemia patients. Leuk. Res. 28 (2004) 1313-1322
38. Agteresch H.J. Randomised clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 14 (2003) 639-644
39. Haskell C.M., et al. Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med. Pediatr. Oncol. 27 (1996) 165-173
40. Haskell C.M. Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest. New Drugs 16 (1998) 81-85
41. 11 receptor in stably transfected haematological cell lines. Mol. Cell. Biochem. 213 (2000) 75-81
42. 5 receptor on satellite cells. J. Cell Biol. 158 (2002) 345-355
43. Greig A.V., et al. Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes. J. Invest. Dermatol. 120 (2003) 1007-1015
44. Calvert R.C., et al. Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells. Anticancer Res. 24 (2004) 2853-2859
45. 7 nucleotide receptor. J. Biol. Chem. 275 (2000) 26792-26798
46. 7 receptors. J. Biol. Chem. 276 (2001) 125-132
47. 12, a new platelet ADP receptor, target of clopidogrel. Semin. Vasc. Med. 3 (2003) 113-122
48. Nichols K.K., et al. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin. Investig. Drugs 13 (2004) 47-54
49. Janssens R., and Boeynaems J.M. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br. J. Pharmacol. 132 (2001) 536-546
50. +) efflux from cultured human breast cancer cells. Biochim. Biophys. Acta 1712 (2005) 52-61
51. 2 receptors in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 84 (1999) 4085-4091
52. Shabbir M., et al. Anti-neoplastic action of extracellular nucleotides in transitional cell carcinoma is mediated by P2-purinergic receptors. J. Physiol. 551P (2003) C65
53. Pines A., et al. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res. 33 (2005) 4379-4394